Real-World Outcomes of Palbociclib with Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Retrospective Study from Saudi Arabia
Palbociclib demonstrated favorable survival outcomes and a manageable safety profile, with neutropenia being the most common AE. This study provides region-specific real-world evidence supporting the use of Palbociclib in HR+/HER2- MBC. These findings align with global trial data and highlight the importance of individualized treatment in clinical practice.
Authors
- Hatoon Bakhribah
- Abdalrhman H. Alanizi
- Sireen Abdul Rahim Shilbayeh (ORCID: https://orcid.org/0000-0002-5020-6838)
- Reema Alotaibi (ORCID: https://orcid.org/0009-0005-2324-1565)
- Amani S. Alrossies (ORCID: https://orcid.org/0009-0009-5358-0305)
- Ammena Y. Binsaleh
- Reem Qubaiban
- Ahmed S. Alanazi
- Nawal Alsubaie
- Sarah N. Al-Shaiban (ORCID: https://orcid.org/0009-0009-7559-9082)
- Esra’a Khader
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- University of Iowa (US)
- Saad Specialist Hospital (SA)
- King Fahd Medical City (SA)
- Saudi Heart Association (SA)
- King Abdulaziz Hospital (SA)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3390/cancers18081270
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Princess Nourah Bint Abdulrahman University